Cargando…

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

Detalles Bibliográficos
Autores principales:	Rubin, David T, Cohen, Russell D, Sandborn, William J, Lichtenstein, Gary R, Axler, Jeffrey, Riddell, Robert H, Zhu, Cindy, Barrett, Andrew C, Bortey, Enoch, Forbes, William P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Corrigenda
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951008/ https://www.ncbi.nlm.nih.gov/pubmed/28453665 http://dx.doi.org/10.1093/ecco-jcc/jjx052

Ejemplares similares

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis
por: Cuffari, Carmen, et al.
Publicado: (2016)

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
por: Kanazawa, Mimari, et al.
Publicado: (2022)

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
por: Rubin, David T., et al.
Publicado: (2015)

Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study
por: Croft, Nicholas Michael, et al.
Publicado: (2023)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach
por: Christophi, George P, et al.
Publicado: (2016)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
por: Minagawa, Yuki, et al.
Publicado: (2022)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
por: Santos, Yurianna, et al.
Publicado: (2023)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Lack of effect of methotrexate in budesonide-refractory collagenous colitis
por: Münch, Andreas, et al.
Publicado: (2013)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018)

Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies
por: Bosworth, Brian P., et al.
Publicado: (2016)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease
por: Doherty, Glen A, et al.
Publicado: (2009)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
por: Moran, Christopher J., et al.
Publicado: (2018)

A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions
por: Hirono, Haruka, et al.
Publicado: (2018)

Urine Discoloration After Voiding in a Boy With Ulcerative Colitis Using Mesalamine
por: Zeef, Dagmar, et al.
Publicado: (2022)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
por: Shimodate, Yuichi, et al.
Publicado: (2011)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Kangfuxinye Enema Combined with Mesalamine for Ulcerative Colitis: A Systematic Review and GRADE Approach
por: Ren, Peng-wei, et al.
Publicado: (2017)

Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
por: Gomes, Lídia, et al.
Publicado: (2023)

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
por: Yarlas, Aaron, et al.
Publicado: (2021)

Corrigendum to: Chronic refractory angina pectoris: recent progress and remaining challenges
Publicado: (2018)

Long-term safety and efficacy of budesonide in the treatment of ulcerative colitis
por: Iborra, Marisa, et al.
Publicado: (2014)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Mesalamine-Induced Myocarditis and Coronary Vasculitis in a Pediatric Ulcerative Colitis Patient: A Case Report
por: Perez-Colon, Elimarys, et al.
Publicado: (2011)

High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
por: Winter, Harland S., et al.
Publicado: (2014)

The Efficacy and Safety of Mesalamine and Probiotics in Mild-to-Moderate Ulcerative Colitis: A Systematic Review and Meta-Analysis
por: Tian, Chunying, et al.
Publicado: (2020)

Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment
por: Dai, Liang, et al.
Publicado: (2021)

19144 Effect of Mesalamine on Metabolic Syndrome risk factors in Ulcerative Colitis Patients: A Retrospective study
por: Castillo, Eliseo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6iu5dqkbsim2j8872ds4tdbtq1